Navigation Links
Cancer Drug Gleevec Linked to Muscle Damage

French researchers say the problem can probably strike small percentage of patients

WEDNESDAY, June 18 (HealthDay News) -- French doctors have reported a possible new side effect associated with the cancer drug Gleevec (imatinib), widely used for the treatment of chronic myeloid leukemia and gastrointestinal stromal tumors.

In a letter published in the June 19 issue of the New England Journal of Medicine, the doctors describe the case of a 25-year-old woman who developed severe rhabdomyolysis while taking imatinib.

Rhabdomyolysis is the breakdown of muscle fibers resulting in the release of muscle fiber contents (myoglobin) into the bloodstream. The condition can cause kidney damage.

The woman was taking imatinib (daily dose of 400 mg) in a clinical trial for the treatment of aggressive fibromatosis (desmoid tumors) that couldn't be treated with surgery. Shortly after the start of drug treatment, the woman experienced symptoms of rhabdomyolysis.

After she stopped taking imatinib, her symptoms ceased. She then agreed to take the drug again while under medical surveillance. Twenty-four hours after she received the first daily dose of 100 mg, she suffered severe symptoms. The drug treatment was halted, and her symptoms disappeared in three days.

The woman's desmoid tumors were treated with radiotherapy, and she has not experienced any recurrence of rhabdomyolysis symptoms.

"We considered our patient's rhabdomyolysis to be induced by imatinib because of the temporal relationship (the rhabdomyolysis occurred within a few days after the initiation of imatinib therapy), the recurrence of rhabdomyolysis with the reintroduction of the drug, and normalization of the creatine kinase level after discontinuation of the drug. Although there is extensive clinical experience with the safe use of imatinib, this observation suggests that the drug may cause severe rhabdomyolysis in a small proportion of patients," the doctors wrote.

Earlier this year, a case report by Greek doctors suggested that imatinib may disrupt ovarian function and impair fertility. It was published as a letter in the New England Journal of Medicine.

More information

The MedlinePlus Medical Encyclopedia has more about rhabdomyolysis.

-- Robert Preidt

SOURCE: New England Journal of Medicine, news release, June 18, 2008

Copyright©2008 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Conventional prognostic factors fail to explain better prostate cancer survival in most Asian men
2. Survival differences by race most apparent in advanced stages of breast cancer
3. MRI finds breast cancer before it becomes dangerous
4. Investigators uncover intriguing clues to why persistent acid reflux sometimes turns into cancer
5. Pathway links inflammation, angiogenesis and breast cancer
6. Radiologists encouraged to look beyond cancer for clinically unseen diseases
7. Diet high in meat, fat and refined grains linked to risk for colon cancer recurrence, death
8. Immune deficiency linked to a type of eye cancer
9. Drop in breast cancer incidence linked to hormone use, not mammograms
10. Breast cancer prevention practices vary across Canada
11. First biomarker discovered that predicts prostate cancer outcome
Post Your Comments:
(Date:11/27/2015)... ... November 27, 2015 , ... Lizzie’s Lice Pickers just announced a special promotion ... off of their purchase of lice treatment product. In addition, customers will receive a ... company spokesperson. “Finding lice is a sure way to ruin the holidays, so we ...
(Date:11/27/2015)... Viejo, CA (PRWEB) , ... November 27, 2015 , ... ... for use in Final Cut Pro X. With ProSidebar: Fasion, video editors can ... or use ProSidebar as a minimalist title opener. Utilize presets featuring self-animating drop ...
(Date:11/27/2015)... ... 2015 , ... Consistent with the Radiology Business Management ... Radiology Marketing Programs meeting will showcase some of the best 2015 radiology ... Palace in Las Vegas with a pre-conference session on a collaborative approach for ...
(Date:11/27/2015)... ... November 27, 2015 , ... A simply groundbreaking television series, ... interesting show that delves into an array of issues that are presently affecting Americans. ... from open dialogue, this show is changing the subjects consumers focus on, one episode ...
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... ... Health-E-minds, an innovative online platform for mental health and wellness consultation, has collaborated ... This partnership will bridge the knowledge gap experienced by parents and bring advice ...
Breaking Medicine News(10 mins):
(Date:11/27/2015)... , Nov. 27, 2015  Lannett Company, ... it has completed the acquisition of Kremers Urban ... subsidiary of global biopharmaceuticals company UCB S.A. (Euronext: ... Lannett has acquired KU from UCB for ... certain adjustments, including a customary working capital adjustment, ...
(Date:11/26/2015)... , 26 november 2015 ... kondigt de geplande investering aan van ten ... de laboratoria en het mondiale hoofdkantoor in ... uitbreiding zal resulteren in extra kantoorruimte en ... aan de groeiende behoeften van de farmaceutische ...
(Date:11/26/2015)... 26, 2015 3D bioprinting market ... to a new report by Grand View Research Inc. Rising ... which demands kidney transplantation is expected to boost the market ... for organ transplantation. --> 3D bioprinting market ... to a new report by Grand View Research Inc. Rising ...
Breaking Medicine Technology: